Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
Beta-blocker-based antihypertensive therapy significantly reduces cardiovascular risk in hypertension compared with placebo or no treatment. Atenolol was an appropriate comparator in the LIFE study. As the results of the LIFE study and other recent trials demonstrate superiority of newer agents over atenolol, this agent is not an appropriate reference drug for future trials of cardiovascular risk in hypertension.
Functional improvement in patients with hemorrhagic stroke after in-patient rehabilitation was predicted by age, pre-training functional level, and cognitive abilities measured at admission.